General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises Neurogene in US$115 Million Series B Financing

December 17, 2020
A Boston-based emerging companies team advises the biotechnology company in the funding round.

Neurogene Inc., a company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, has announced the completion of a US$115 million Series B financing. The financing round was led by EcoR1 Capital, with participation from existing investors Redmile Group, Samsara BioCapital, Cormorant Asset Management and an undisclosed leading healthcare investment fund. New investors include funds and accounts managed by BlackRock, funds managed by Janus Henderson Investors, Casdin Capital, Avidity Partners, Ascendant BioCapital, Arrowmark Partners, and Alexandria Venture Investments. 

Latham & Watkins LLP represents Neurogene Inc. in the financing with a Boston-based emerging companies team led by partner Stephen Ranere, with associates Belinda King and Martha Anderson.